168 / 172
168
180.Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu
Z, et al. Golimumab, a new human anti-tumor necrosis factor
alpha antibody, administered intravenously in patients with
active rheumatoid arthritis: Forty-eight-week efficacy and
safety results of a phase III randomized, double-blind,
placebo-controlled study. Arthritis Rheum 2010;62:917-28.
181.Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S,
et al. Golimumab in patients with active rheumatoid arthritis
despite treatment with methotrexate: a randomized, double-
blind, placebo-controlled, dose-ranging study. Arthritis
Rheum 2008;58:964-75.
182.Clifford DB, Ances B, Costello C, Rosen-Schmidt S,
Andersson M, Parks D, et al. Rituximab-associated
progressivemultifocal leukoencephalopathy in rheumatoid
arthritis. Arch Neurol 2011;68:1156-64.
183. Greenwald MW, Shergy WJ, Kaine JL, Sweetser MT,
Gilder K, Linnik MD. Evaluation of the safety of rituximab in
combination with a tumor necrosis factor inhibitor and
methotrexate in patients with active rheumatoid arthritis:
results from a randomized controlled trial. Arthritis Rheum
2011;63:622-32.
184. Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van
Vollenhoven RF, Stohl W, et al. Inhibition of joint damage and
improved clinical outcomes with rituximab plus methotrexate
in early active rheumatoid arthritis: the IMAGE trial. Ann
Rheum Dis 2011;70:39-46.
185. Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carreño
L, Armstrong G, et al. Efficacy and safety of various repeat
treatment dosing regimens of rituximab in patients with active
rheumatoid arthritis: results of a Phase III randomized study
(MIRROR). Rheumatology (Oxford) 2010;49:1683-93.
186. Keystone E, Burmester GR, Furie R, Loveless JE, Emery P,
Kremer J, et al. Improvement in patient-reported outcomes in a
rituximab trial in patients with severe rheumatoid arthritis